Nektar Therapeutics

Nektar Therapeutics

Nektar Therapeutics

Overview
Date Founded

1998

Headquarters

455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158

Type of Company

Public

Employees (Worldwide)

718

Industries

Pharmaceuticals
Biotechnology
Hospitals & Patient Services

Company Description

Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

Contact Data
Trying to get in touch with decision makers at Nektar Therapeutics? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Senior Vice President, Chief Operating Officer & Chief Financial Officer

Chief Financial Officer

Secretary, Senior Vice President & General Counsel

Senior Vice President & Chief Commercial Officer

Chief Scientific Officer & Chief Research & Development

Senior Vice President, Clinical Development & Chief Medical Officer

Senior Vice President, Finance & Chief Accounting Officer

Senior Vice President & Chief Medical Officer

Senior Vice President & Head of Immunology

Board of Directors

Chief Medical Officer & Executive Vice President at Intuitive Surgical, Inc.

Founder at Numenor Ventures LLC

Director at Personalis, Inc.

Executive Vice President, Chief Commercial Officer at BioMarin Pharmaceutical, Inc.

President & Chief Executive Officer at Nektar Therapeutics

Chief Executive Officer at AlloVir, Inc.

Co-Founder at Incyte Corp.

Paths to Nektar Therapeutics
Potential Connections via
Relationship Science
You
Nektar Therapeutics
Owners & Shareholders
Details Hidden

Maverick Capital’s investment process is driven by intensive, fundamental bottom-up research. They deploy capital to individual investment opportunities that it believes offer the highest returns relative to risk, regardless of index weightings, market capitalization or style orientations. Their research is augmented by a top-down view of individual industries, as well as the efforts of their quantitative research team. While fundamentals still drive security selection, the quantitative research effort plays an important role in Maverick’s portfolio construction, security selection and risk management. The firm’s investment team is organized into six industry sector teams: Consumer, Financials, Healthcare, Industrials, Media & Telecom and Technology. The industry sector teams are supported by two discipline research teams: private investments and quantitative. The firm’s founder – Lee S. Ainslie III – has ultimate responsibility for all portfolio decisions for Maverick Funds and related Separate Account Clients.

Details Hidden

Bellevue AM is an active, fundamental research-based manager which utilizes a bottom-up investment and anti-cyclical approach that aims to generate above-average returns while keeping risk under control and well monitored. They screen and invest in promising family and owner-managed companies based in Switzerland or the broader European continent through our family of Entrepreneur funds. The firm has become very adept at identifying high growth potential in new and emerging markets, particularly on the African continent.

Details Hidden

Camber Capital Management seeks to generate capital appreciation without regard to current income by investing primarily in publicly-traded common stocks of healthcare companies across a variety of industries including healthcare services and facilities, pharmaceuticals, medical products and devices and biotechnology. Although most of their investments are within the healthcare industry, the firm may occasionally invest in other sectors if more attractive opportunities are identified. Camber Capital Management employs a fundamental, bottom-up research approach designed to identify high-quality companies whose inherent value is not adequately reflected in a company's market valuation.

Recent Transactions
Details Hidden

Nektar Therapeutics issued USD Common Stock

Details Hidden

Nektar Therapeutics issued USD Common Stock

Details Hidden

Nektar Therapeutics issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Accountant

Advised onNektar Therapeutics purchases Shearwater Corp.

Underwriter

Advised onNektar Therapeutics issued USD Common Stock

Underwriter

Advised onNektar Therapeutics issued USD Common Stock

Legal Advisor

Advised onNektar Therapeutics issued USD Common Stock

Legal Advisor

Advised onNektar Therapeutics issued USD Common Stock

Head, Healthcare Investment Banking

Advised onNektar Therapeutics issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner, San Diego at Cooley LLP

Legal Advisor

Partner at Cadwalader, Wickersham & Taft LLP

Legal Advisor

Partner at Sidley Austin LLP

Clients

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Key Stats and Financials As of 2020
Market Capitalization
$2.14B
Total Enterprise Value
$2.29B
Earnings Per Share
$-2.49
Revenue
$153M
EBITDAMargin
-240.28%
TEVNet Income
-5.16x
Debt TEV
0.14x
Enterprise Value / Sales
15x
Total Debt
$320M
Total Equity
$1.08B
EBITDA
$-367M
Net Profit
$-444M
Three Year Compounded Annual Growth Rate Of Revenue
-20.79%
Political Donations
$6,500
2012
Investments
Details Hidden

Pearl Therapeutics, Inc. develops therapies for the treatment of chronic respiratory diseases. It offers respiratory product development, high quality therapies for COPD, Asthma and treatment and prevention of chronic respiratory diseases and asthma. The company was founded in 2006 by Sarvajna Dwivedi and is headquartered in Redwood City, CA.

Suppliers
Pharmicell Co., Ltd. Pharmaceuticals | Seoul, South Korea

Pharmicell Co., Ltd. is engaged in the development of stem cell based pharmaceuticals and technologies. It operates through the Bio and Chemical Business Divisions. The Bio division provides cosmetics, cell for researches, medical testing equipment, and others. The Chemical division offers nucleoside, agricultural pesticides, fire retardant materials, and others. The company was founded on August 20, 1968 and is headquartered in Seoul, South Korea.

Certara, Inc. Computer Software | Princeton, NJ

Certara, Inc. engages in the provision of software and technology enables services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017 and is headquartered in Princeton, NJ.

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government. Johnson & Johnson is headquartered in New Brunswick, New Jersey, the consumer division being located in Skillman, New Jersey. The corporation includes some 250 subsidiary companies with operations in 60 countries and products sold in over 175 countries. Johnson & Johnson had worldwide sales of $82.6 billion during calendar year 2020. Johnson & Johnson's brands include numerous household names of medications and first aid supplies. Among its well-known consumer products are the Band-Aid Brand line of bandages, Tylenol medications, Johnson's Baby products, Neutrogena skin and beauty products, Clean & Clear facial wash and Acuvue contact lenses. Johnson & Johnson's pharmaceutical arm is Janssen Pharmaceutica.

Bausch Health Cos., Inc. Pharmaceuticals - Laval, Canada

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

AstraZeneca Plc Pharmaceuticals - Cambridge, United Kingdom

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Nektar Therapeutics. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Nektar Therapeutics's profile does not indicate a business or promotional relationship of any kind between RelSci and Nektar Therapeutics.